JP2012519653A5 - - Google Patents

Download PDF

Info

Publication number
JP2012519653A5
JP2012519653A5 JP2011537754A JP2011537754A JP2012519653A5 JP 2012519653 A5 JP2012519653 A5 JP 2012519653A5 JP 2011537754 A JP2011537754 A JP 2011537754A JP 2011537754 A JP2011537754 A JP 2011537754A JP 2012519653 A5 JP2012519653 A5 JP 2012519653A5
Authority
JP
Japan
Prior art keywords
group
optionally substituted
substituent
substituted
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011537754A
Other languages
English (en)
Japanese (ja)
Other versions
JP5645839B2 (ja
JP2012519653A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2010/054073 external-priority patent/WO2010101302A1/en
Publication of JP2012519653A publication Critical patent/JP2012519653A/ja
Publication of JP2012519653A5 publication Critical patent/JP2012519653A5/ja
Application granted granted Critical
Publication of JP5645839B2 publication Critical patent/JP5645839B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011537754A 2009-03-05 2010-03-04 Ｃｄｃ７キナーゼ阻害剤としてのチエノピリミジン Active JP5645839B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US15776009P 2009-03-05 2009-03-05
US61/157,760 2009-03-05
US29499110P 2010-01-14 2010-01-14
US61/294,991 2010-01-14
US29833810P 2010-01-26 2010-01-26
US61/298,338 2010-01-26
PCT/JP2010/054073 WO2010101302A1 (en) 2009-03-05 2010-03-04 Thienopyrimidine as cdc7 kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2012519653A JP2012519653A (ja) 2012-08-30
JP2012519653A5 true JP2012519653A5 (enExample) 2013-03-07
JP5645839B2 JP5645839B2 (ja) 2014-12-24

Family

ID=42112336

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011537754A Active JP5645839B2 (ja) 2009-03-05 2010-03-04 Ｃｄｃ７キナーゼ阻害剤としてのチエノピリミジン

Country Status (4)

Country Link
US (1) US8691828B2 (enExample)
EP (1) EP2403857B1 (enExample)
JP (1) JP5645839B2 (enExample)
WO (1) WO2010101302A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3533797B1 (en) 2010-02-17 2023-12-20 Takeda Pharmaceutical Company Limited Heterocyclic compound
SG11201402765TA (en) 2011-12-30 2014-06-27 Hanmi Pharm Ind Co Ltd THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES
US9974795B2 (en) 2014-01-31 2018-05-22 Carna Biosciences, Inc. Anticancer agent composition
CN110381950B (zh) * 2017-05-21 2020-09-04 南京正济医药研究有限公司 作为抗癌剂的取代的[5,6]环-4(3h)-嘧啶酮
GB201807147D0 (en) 2018-05-01 2018-06-13 Oncologica Uk Ltd Therapeutic combination
NL2021185B1 (en) 2018-06-26 2020-01-06 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Combination Therapy and Use Thereof for Treating Cancer
CA3113621A1 (en) 2018-09-24 2020-04-02 Sierra Oncology, Inc. Methods of treatment of cancer comprising cdc7 inhibitors
US20230101747A1 (en) * 2019-12-06 2023-03-30 Schrödinger, Inc. Cyclic compounds and methods of using same
CN116490507A (zh) 2020-09-10 2023-07-25 薛定谔公司 用于治疗癌症的杂环包缩合cdc7激酶抑制剂
CN117120447A (zh) * 2021-03-18 2023-11-24 薛定谔公司 环状化合物和其使用方法
TW202300150A (zh) * 2021-03-18 2023-01-01 美商薛定諤公司 環狀化合物及其使用方法
CN115260211B (zh) * 2021-04-29 2024-02-06 长春金赛药业有限责任公司 含噻吩稠环类衍生物、药物组合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040176361A1 (en) * 2001-05-23 2004-09-09 Masakazu Fujio Fused heterocyclic compound and medicinal use thereof
CN101152185B (zh) * 2003-06-06 2010-12-08 阿里克斯股份公司 杂环化合物作为scce抑制剂的用途
WO2005014572A1 (en) 2003-08-08 2005-02-17 Pharmacia Italia S.P.A. Pyrimidylpyrrole derivatives active as kinase inhibitors
US7279575B2 (en) 2003-08-08 2007-10-09 Pfizer Italia S.R.L. Pyrimidylpyrrole derivatives active as kinase inhibitors
WO2005095386A1 (en) 2004-03-30 2005-10-13 Chiron Corporation Substituted thiophene derivatives as anti-cancer agents
US20080221107A1 (en) * 2005-07-15 2008-09-11 Astrazeneca Ab Therapeutic Agents
US20070142414A1 (en) * 2005-12-16 2007-06-21 Pharmacia Italia S.P.A. N-substituted pyrrolopyridinones active as kinase inhibitors
WO2008072779A1 (ja) * 2006-12-13 2008-06-19 Aska Pharmaceutical Co., Ltd. キノキサリン誘導体
AU2007332439A1 (en) * 2006-12-13 2008-06-19 Aska Pharmaceutical Co., Ltd. Therapeutic agent for urinary tract disease

Similar Documents

Publication Publication Date Title
JP2011132222A5 (enExample)
JP2013536188A5 (enExample)
JP2018515434A5 (enExample)
AR084412A1 (es) Compuestos de piridina fusionados, utiles como inhibidores de caseina quinasa, y las composiciones farmaceuticas que los contienen
AR087148A1 (es) Imidazopiridazinas
CA3080968A1 (en) Modulators of the integrated stress pathway
AR095347A1 (es) Compuestos orgánicos
CA3080948A1 (en) Modulators of the integrated stress pathway
MX361020B (es) Procesos para preparar compuestos heterociclicos, incluida trans-7-oxo-6-(sulfooxi)-1,6-diazabiciclo [3,2,1]octano-2-carboxam ida y sales de la misma.
EA201391209A1 (ru) Мостиковые производные пиперидина
JP2016532715A5 (enExample)
JP2018527295A5 (enExample)
AR088441A1 (es) Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
JP2013542218A5 (enExample)
AR091858A1 (es) INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
JP2017511321A5 (enExample)
RU2017123038A (ru) 6,7-ДИГИДРОПИРАЗОЛО[1,5-a]ПИРАЗИН-4(5H)-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ОТРИЦАТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ MGLUR2
RU2018114518A (ru) Новые бициклические соединения в качестве двойных ингибиторов аутотаксина (atx)/карбоангидразы (ca)
JP2010155827A5 (enExample)
JP2013510178A5 (enExample)
JP2013542213A5 (enExample)
JP2017518344A5 (enExample)
JP2013515037A5 (enExample)
HK1210771A1 (zh) 氮杂吲哚衍生物
JP2011506566A5 (enExample)